Blood-based tumor mutational burden impacts clinical outcomes of immune checkpoint inhibitor treated breast and prostate cancers

Blood-based tumor mutational burden impacts clinical outcomes of immune checkpoint inhibitor treated breast and prostate cancers

Abstract Background Breast and prostate tumors are known to be less responsive to immune checkpoint inhibitors (ICIs). Tissue-based tumor mutation burden (tTMB) has emerged as a predictive biomarker of response to ICIs, including in these “cold tumors”. In clinical practice, when tTMB is not availab...

Full description

Bibliographic Details
Main Authors: Reagan M. Barnett, Albert Jang, Sree Lanka, PIngfu Fu, Leslie A. Bucheit, Hani Babiker, Alan Bryce, Haley M. Meyer, Yujin Choi, Casey Moore, Rohan Garje, Xin Gao, Dae Won Kim, Richard Y. Chang, Pat Gulhati, Ryne Ramaker, Rani Bansal, Tian Zhang, A. Oliver Sartor, Andrew J. Armstrong, Mehmet A. Bilen, Pedro Barata
Format: Article
Language:English
Published: Nature Portfolio 2024-12-01
Series:Communications Medicine
Online Access:https://doi.org/10.1038/s43856-024-00687-5

Internet

https://doi.org/10.1038/s43856-024-00687-5

Similar Items